Fig. 3.

GeneSight guidance amplifies the tendency of clinicians of unguided patients to shift patients to genetically appropriate medications. From baseline to the end of the 8- or 10-week studies, 36.4% of the 99 GeneSight-guided patients switched to medications whose most severe category status was green, while 39.1% were switched off of medications whose most severe category status was red. Far smaller proportions (6.7 and 7.1%, respectively) of the 117 TAU subjects were switched in the same directions.